BioSpace News Archive

Policy

Novavax’s Updated COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan

Novavax, Inc. announced that the Taiwan Food and Drug Administration has granted emergency use authorization for Nuvaxovid™ XBB.1.5 dispersion for injection COVID-19 Vaccine for active immunization to prevent COVID-19 in individuals aged 12 and older.

December 18, 2023
·
10 min read
Genetown

Anagenex and Nimbus Announce a Multi-Target Collaboration to Discover Small Molecule Therapeutics for Multiple Indications

Anagenex and Nimbus Therapeutics announced they have initiated a research collaboration.

December 18, 2023
·
3 min read
Biotech Beach

Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury

Lineage Cell Therapeutics, Inc. announced today that the Company has submitted an Investigational New Drug amendment (INDa) to the U.S. Food and Drug Administration (FDA), for OPC1.

December 18, 2023
·
10 min read
BioMidwest

ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2024”

ZyVersa Therapeutics, Inc. announces that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President, will participate in BIO Partnering @ JPM being held January 8-12, 2024 in San Francisco.

December 18, 2023
·
5 min read
Business

Grant of Options to Directors and Officers

Arch Biopartners Inc., announced that its Board of Directors has granted a total of 350,000 stock options to directors and officers pursuant to the Company’s stock option plan and the requirements of the TSX Venture Exchange.

December 18, 2023
·
3 min read
Lone Star Bio

Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression

Nexalin Technology, Inc. reported the results of a study in patients with treatment-resistant depression, concerning the potential therapeutic benefits of its second-generation, 15 milliamp neurostimulation device, which indicated a substantial and statistically significant benefit in patients.

December 18, 2023
·
6 min read
Drug Development

Mirum Pharmaceuticals Announces Data from EMBARK Phase 2b Study for Biliary Atresia

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced top-line results of the Phase 2 EMBARK study evaluating LIVMARLI® (maralixibat) oral solution versus placebo given as an adjuvant therapy to Kasai surgery in patients with biliary atresia.

December 18, 2023
·
5 min read
Drug Development

Avstera Therapeutics Announces FDA Clearance of IND Application for AVS100, a Novel Highly Selective HDAC6 Inhibitor Targeting Solid Tumors

Avstera Therapeutics Corp, today announced the U.S. FDA clearance of its Investigational New Drug application (IND) for AVS100, a novel highly selective oral HDAC6 inhibitor intended to treat locally advanced or metastatic solid tumors in a Phase I clinical study.

December 18, 2023
·
5 min read
Genetown

Trinity Life Sciences Institutes a Formal Cell and Gene Therapy Center of Excellence

Trinity Life Sciences, a leader in global life sciences commercialization solutions, introduces a Cell & Gene Therapy Center of Excellence that supports life sciences companies in successfully commercializing a C> asset.

December 18, 2023
·
4 min read
Lone Star Bio

CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin

CNS Pharmaceuticals, Inc. today announced the recommendation of the independent Data Safety Monitoring Board (DSMB) that the Company’s ongoing global, potentially pivotal trial of the investigational agent, Berubicin for the treatment of glioblastoma multiforme (GBM) continue without any modification.

December 18, 2023
·
5 min read